Molecular Pharmacology (USA) Ltd - ESG Rating & Company Profile powered by AI
The analysis of Molecular Pharmacology (USA) Ltd is assembled by All Street Sevva using advanced AI. The page contains a free Environmental, Social and Governance report covering Molecular Pharmacology (USA) Ltd. This dashboard contains a Q&A table for Molecular Pharmacology (USA) Ltd.
Molecular Pharmacology (USA) Ltd in the Biotechnology & Medical Research industry gained a UN SDG ESG Transparency Score of 8.0; made up of an environmental score of 8.0, social score of 8.0 and governance score of 8.0.
8.0
High ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Molecular Pharmacology (USA) Ltd | 8.0 | High |
1 | Analytik Jena AG | 8.0 | High |
1 | Amniotics AB (publ) | 8.0 | High |
... | ... | ... | |
182 | Wesana Health Holdings Inc | 0.0 | Low |
182 | rEVO Biologics Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Molecular Pharmacology (USA) Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Molecular Pharmacology (USA) Ltd disclose current and historical energy intensity?
Does Molecular Pharmacology (USA) Ltd report the average age of the workforce?
Does Molecular Pharmacology (USA) Ltd reference operational or capital allocation in relation to climate change?
Does Molecular Pharmacology (USA) Ltd disclose its ethnicity pay gap?
Does Molecular Pharmacology (USA) Ltd disclose cybersecurity risks?
Does Molecular Pharmacology (USA) Ltd offer flexible work?
Does Molecular Pharmacology (USA) Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Molecular Pharmacology (USA) Ltd disclose the number of employees in R&D functions?
Does Molecular Pharmacology (USA) Ltd conduct supply chain audits?
Does Molecular Pharmacology (USA) Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Molecular Pharmacology (USA) Ltd conduct 360 degree staff reviews?
Does Molecular Pharmacology (USA) Ltd disclose the individual responsible for D&I?
Does Molecular Pharmacology (USA) Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Molecular Pharmacology (USA) Ltd disclose current and / or historical scope 2 emissions?
Does Molecular Pharmacology (USA) Ltd disclose water use targets?
Does Molecular Pharmacology (USA) Ltd have careers partnerships with academic institutions?
Did Molecular Pharmacology (USA) Ltd have a product recall in the last two years?
Does Molecular Pharmacology (USA) Ltd disclose incidents of discrimination?
Does Molecular Pharmacology (USA) Ltd allow for Work Councils/Collective Agreements to be formed?
Has Molecular Pharmacology (USA) Ltd issued a profit warning in the past 24 months?
Does Molecular Pharmacology (USA) Ltd disclose parental leave metrics?
Does Molecular Pharmacology (USA) Ltd disclose climate scenario or pathway analysis?
Does Molecular Pharmacology (USA) Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Molecular Pharmacology (USA) Ltd disclose the pay ratio of women to men?
Does Molecular Pharmacology (USA) Ltd support suppliers with sustainability related research and development?
Does Molecular Pharmacology (USA) Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Molecular Pharmacology (USA) Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Molecular Pharmacology (USA) Ltd involved in embryonic stem cell research?
Does Molecular Pharmacology (USA) Ltd disclose GHG and Air Emissions intensity?
Does Molecular Pharmacology (USA) Ltd disclose its waste policy?
Does Molecular Pharmacology (USA) Ltd report according to TCFD requirements?
Does Molecular Pharmacology (USA) Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Molecular Pharmacology (USA) Ltd disclose energy use targets?
Does Molecular Pharmacology (USA) Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Molecular Pharmacology (USA) Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Molecular Pharmacology (USA) Ltd
These potential risks are based on the size, segment and geographies of the company.
Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd., develops analgesic and anti-inflammatory molecule, known as Tripeptofen for the treatment of common every-day pain. Its products are available in various dosage forms, formulations, line extensions, and package configurations. The company focuses on marketing its products through pharmaceutical distributors, and through collaborative dealings with companies in the United States and Europe. It also has an agreement with Dermatology Development Corporation to develop and market a range of therapeutic, cosmetic, and cosmecutical products based on the ThermaLIFE product range and its active ingredient. The company is based in Perth, Australia. Molecular Pharmacology (USA) Limited is a subsidiary of PharmaNet Group Limited.